Table 2

Summary of treatment-emergent adverse events (TEAE)

Embedded Image

  • *Number of events per 100 patient-years.

  • †n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term.

  • ‡Cervix carcinoma.

  • §Including following preferred terms: alanine aminotransferase increased, aspartate aminotransferase increased, γ-glutamyltransferase increased, hepatic function abnormal, hepatic enzyme increased, hepatic steatosis, hyperbilirubinaemia, liver disorder, liver function test abnormal; MedDRA V.14.1.

  • AE, adverse events; CZP, certolizumab pegol; MTX, methotrexate; PBO, placebo.